Nurix Therapeutics, Inc. Income Statement
NRIX / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Nurix Therapeutics, Inc. reported $84M in revenue and $264M in net loss for FY2025. Revenue has grown at a 18.0% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $29.8M | $31.1M | $17.8M | $31.1M |
| SG&A Expense | $52.7M | $45.9M | $42.9M | $31.2M | $8.3M | $16.3M | $8.3M |
| R&D Expense | $316.9M | $221.6M | $189.1M | $116.4M | $45.0M | $66.5M | $45.0M |
| Operating Income | -$285.7M | -$213.0M | -$155.1M | -$117.9M | -$22.2M | -$65.0M | -$22.2M |
| Income Tax | $760.0K | $270.0K | $0 | $131.0K | $239.0K | -$20.5M | $239.0K |
| Net Income | -$264.5M | -$193.6M | -$143.9M | -$117.2M | -$21.7M | -$43.2M | -$21.7M |
| EPS (Basic) | -$2.65 | -$3.71 | -$3.71 | -$2.73 | - | - | - |
| EPS (Diluted) | -$2.65 | -$3.71 | -$3.71 | -$2.73 | -$6.59 | -$6.59 | - |
| Shares Outstanding | 75.9M | 48.7M | 47.2M | 44.7M | 38.9M | 3.6M | 3.3M |
| Operating Margin | -340.2% | -390.5% | -201.4% | -396.3% | -71.5% | -364.7% | -71.5% |
| Profit Margin | -314.9% | -354.9% | -187.0% | -393.9% | -69.7% | -242.7% | -69.7% |